Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucerastat long-term extension study in adults with Fabry disease
2024-513884-20-00Phase 3Completed
- Sponsor
- Idorsia
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of lucerastat in Fabry disease (FD), sponsored by Idorsia. Primary endpoint: Treatment-emergent adverse events and serious adverse events. Started Mar 2019; status: completed.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2024-513884-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513884-20-00.